Where does Mersana Therapeutics, Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Mersana Therapeutics, Inc. ranks #11,003 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Mersana Therapeutics, Inc. hold?

Mersana Therapeutics, Inc. holds 28 US utility patents granted between 2015 and 2024, spanning 9 technology areas.

What is Mersana Therapeutics, Inc.'s Innovation Score?

Mersana Therapeutics, Inc. has an Innovation Score of 41.2 out of 100 (top 34% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Mersana Therapeutics, Inc. focus on?

Mersana Therapeutics, Inc.'s top technology area is A61K (Preparations FOR Medical, Dental OR Toiletry Purposes) with 26 patents, ranking #871 of 7,163 assignees active in that subclass. Grants appear in 9 CPC subclasses total.

Is Mersana Therapeutics, Inc.'s patent grant rate increasing or decreasing?

Mersana Therapeutics, Inc.'s recent grant velocity is +55% compared to the prior five-year period (grant years, not application filing dates). This indicates accelerating grant output.

What does claim depth mean for Mersana Therapeutics, Inc.'s patents?

Mersana Therapeutics, Inc.'s patents average 20.4 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Mersana Therapeutics, Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

Mersana Therapeutics, Inc.

USPTO PatentsView assignee record - 28 granted patents across 9 technology areas, recorded in grant years 2015–2024. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61K (Preparations FOR Medical, Dental OR Toiletry Purposes).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Mersana ranks #11,003 of 49,997 tracked US assignees by granted-patent volume, with 28 patents across 9 technology areas.

#11,003
of 49,997 US assignees by volume: Top 34%
by Innovation Score (41.2/100): 20.4
avg claims per patent: +55%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R11003 · US Corporation #11,003 · 28 grants

GRANTS-SMALL · UPPER-Q · PHOTO-FINISH · CPC-NARROW · INNOV-PAR · CLAIMS-DENSE · TYPE-USCORP · VEL-SURGE · BOOK-FULL

GRANTS-SMALL 28 grants
UPPER-Q #11,003/49,997
PHOTO-FINISH Manehu Product…
CPC-NARROW A61K · 9 areas
INNOV-PAR 41.2/100
CLAIMS-DENSE 20.4 claims/avg
TYPE-USCORP US Corporation
VEL-SURGE +55% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Manehu Product Alliance, LLC (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Mersana’s 41.2 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 11.6 pts (28%) Velocity 6.7 pts (16%) Breadth 10.6 pts (26%) Claim depth 12.3 pts (30%)

Qualcomm Incorporated · highest

85
Capital One Financial · near

41
Control Techniques · near

41
Galapagos · near

41
Mersana Therapeutics · this assignee

41
Surpass Industry · near

41
3D Lighting… · lowest

7

What this shows Mersana's Innovation Score is 41.2/100 (top 34% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Mersana?

Each dot is one of Mersana’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Mersana’s own 20.4 claims/patent is ABOVE the 16.6 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Mersana vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Mersana's grants concentrate

Mersana Therapeutics, Inc. is a focused PatentsView assignee: 9 CPC subclasses with 92.9% of grants classified under A61K (Preparations FOR Medical, Dental OR Toiletry Purposes). Peak complete grant year is 2017 (5 grants) versus a trough of 1 in 2015. By volume, Mersana sits between Manehu Product Alliance, LLC and Mylan Laboratories Limited.

Mersana's three-year grant acceleration

Mersana Therapeutics, Inc. shows 9 grants in 2022–2024 against only 9 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Manehu Product Al…

28
Manicka Institute

28
Measurement Incor…

28
Medizinische Univ…

28
Metal Raptor

28
Mirka

28
Mux

28
Mylan Laboratories

28
Mersana Therapeut… ◀

28

What this shows Mersana holds 28 patents at rank #11,007, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Mersana

By rank, the assignees closest to #11,007 in granted patent volume.

Leaders in A61K (Preparations FOR Medical)

Other assignees with the most granted patents in Mersana's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Mersana, neither rank-band nor same-CPC leaders (those blocks stay above). In A61K (Preparations FOR Medical), Mersana ranks #871 of 7,163 assignees by patent count in that subclass.

Similar innovation score

Nearest assignees by Innovation Score (41 here).

Control Techniques Limited 41 Capital One Financial Corporation 41 Surpass Industry Co., Ltd. 41 Galapagos NV 41

Mersana's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

41 Top 34% higher than 66% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2024

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

Mersana Therapeutics, Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	1	3.6%
2016	1	3.6%
2017	5	17.9%
2018	3	10.7%
2019	1	3.6%
2020	5	17.9%
2021	3	10.7%
2022	2	7.1%
2023	3	10.7%
2024	4	14.3%

Which technologies does Mersana Therapeutics, Inc. patent most?

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 26

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 22

C07K - Peptides 15

C08G - Macromolecular Compounds Obtained Otherwise Than BY Reactions Only Involving Unsaturated Carbon-to-carbon Bonds 7

C07D - Heterocyclic Compounds 5

C08L - Compositions OF Macromolecular Compounds 4

G01N - Investigating OR Analysing Materials BY Determining Their Chemical OR Physical Properties 1

C12N - Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media 1

C07C - Acyclic OR Carbocyclic Compounds 1

Top 9 of 9 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Mersana Therapeutics, Inc.'s patent record in context - here's where to go next.

Mersana Therapeutics, Inc.'s lead technology class is A61K (Preparations FOR Medical, Dental OR Toiletry Purposes), 92.9% of its portfolio - see every assignee active in that class. Explore A61K
Ranked #11,003 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Mersana Therapeutics, Inc. against Manehu Product Alliance, LLC, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 41.2/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.